Doxorubicin-loaded cell-derived nanovesicles: an alternative targeted approach for anti-tumor therapy
Cell-derived nanovesicles (CDNs) are an emerging class of biological drug delivery systems (DDS) that retain the characteristics of the cells they were derived from, without the need for further surface functionalization. CDNs are also biocompatible, being derived from natural sources and also take...
Saved in:
Main Authors: | , , , , , |
---|---|
Other Authors: | |
Format: | Article |
Language: | English |
Published: |
2017
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/84349 http://hdl.handle.net/10220/43588 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
id |
sg-ntu-dr.10356-84349 |
---|---|
record_format |
dspace |
spelling |
sg-ntu-dr.10356-843492020-11-01T05:31:56Z Doxorubicin-loaded cell-derived nanovesicles: an alternative targeted approach for anti-tumor therapy Goh, Wei Jiang Lee, Choon Keong Zou, Shui Woon, Esther Czarny, Bertrand Pastorin, Giorgia School of Materials Science & Engineering Lee Kong Chian School of Medicine (LKCMedicine) Cell-derived nanovesicles Cell targeting Cell-derived nanovesicles (CDNs) are an emerging class of biological drug delivery systems (DDS) that retain the characteristics of the cells they were derived from, without the need for further surface functionalization. CDNs are also biocompatible, being derived from natural sources and also take advantage of the enhanced permeability and retention effect due to their nanodimensions. Furthermore, CDNs derived from monocytes were shown to have an in vivo targeting effect, accumulating at the tumor site in a previous study conducted in a mouse tumor model. Here, we report a systematic approach pertaining to various loading methods of the chemotherapeutic drug doxorubicin into our CDNs and examine the differential cellular uptake of drug-loaded CDNs in cancerous (HeLa) and healthy (HEK293) cell lines. Lastly, we proved that the addition of doxorubicin-loaded CDNs to the HeLa and HEK293 co-cultures showed a clear discrimination toward cancer cells at the cellular level. Our results further reinforce the intriguing potential of CDNs as an alternative targeted strategy for anticancer therapy. Published version 2017-08-16T04:19:44Z 2019-12-06T15:43:17Z 2017-08-16T04:19:44Z 2019-12-06T15:43:17Z 2017 Journal Article Goh, W. J., Lee, C. K., Zou, S., Woon, E., Czarny, B., & Pastorin, G. (2017). Doxorubicin-loaded cell-derived nanovesicles: an alternative targeted approach for anti-tumor therapy. International Journal of Nanomedicine, 12, 2759-2767. 1176-9114 https://hdl.handle.net/10356/84349 http://hdl.handle.net/10220/43588 10.2147/IJN.S131786 en International Journal of Nanomedicine © 2017 Goh et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). 9 p. application/pdf |
institution |
Nanyang Technological University |
building |
NTU Library |
continent |
Asia |
country |
Singapore Singapore |
content_provider |
NTU Library |
collection |
DR-NTU |
language |
English |
topic |
Cell-derived nanovesicles Cell targeting |
spellingShingle |
Cell-derived nanovesicles Cell targeting Goh, Wei Jiang Lee, Choon Keong Zou, Shui Woon, Esther Czarny, Bertrand Pastorin, Giorgia Doxorubicin-loaded cell-derived nanovesicles: an alternative targeted approach for anti-tumor therapy |
description |
Cell-derived nanovesicles (CDNs) are an emerging class of biological drug delivery systems (DDS) that retain the characteristics of the cells they were derived from, without the need for further surface functionalization. CDNs are also biocompatible, being derived from natural sources and also take advantage of the enhanced permeability and retention effect due to their nanodimensions. Furthermore, CDNs derived from monocytes were shown to have an in vivo targeting effect, accumulating at the tumor site in a previous study conducted in a mouse tumor model. Here, we report a systematic approach pertaining to various loading methods of the chemotherapeutic drug doxorubicin into our CDNs and examine the differential cellular uptake of drug-loaded CDNs in cancerous (HeLa) and healthy (HEK293) cell lines. Lastly, we proved that the addition of doxorubicin-loaded CDNs to the HeLa and HEK293 co-cultures showed a clear discrimination toward cancer cells at the cellular level. Our results further reinforce the intriguing potential of CDNs as an alternative targeted strategy for anticancer therapy. |
author2 |
School of Materials Science & Engineering |
author_facet |
School of Materials Science & Engineering Goh, Wei Jiang Lee, Choon Keong Zou, Shui Woon, Esther Czarny, Bertrand Pastorin, Giorgia |
format |
Article |
author |
Goh, Wei Jiang Lee, Choon Keong Zou, Shui Woon, Esther Czarny, Bertrand Pastorin, Giorgia |
author_sort |
Goh, Wei Jiang |
title |
Doxorubicin-loaded cell-derived nanovesicles: an alternative targeted approach for anti-tumor therapy |
title_short |
Doxorubicin-loaded cell-derived nanovesicles: an alternative targeted approach for anti-tumor therapy |
title_full |
Doxorubicin-loaded cell-derived nanovesicles: an alternative targeted approach for anti-tumor therapy |
title_fullStr |
Doxorubicin-loaded cell-derived nanovesicles: an alternative targeted approach for anti-tumor therapy |
title_full_unstemmed |
Doxorubicin-loaded cell-derived nanovesicles: an alternative targeted approach for anti-tumor therapy |
title_sort |
doxorubicin-loaded cell-derived nanovesicles: an alternative targeted approach for anti-tumor therapy |
publishDate |
2017 |
url |
https://hdl.handle.net/10356/84349 http://hdl.handle.net/10220/43588 |
_version_ |
1683494554620133376 |